I can only think of one time in my life when a congressional hearing about health care was actually illuminating. It was 2016, and Mylan CEO Heather Bresch testified on

If we’re being honest, the force that is going to end the ever-escalating trend of PBM-fueled rebates and the accompanying shell game is probably not going to be legislative action,

For more than a quarter-century, I’ve been a member of the National Association of Science Writers, a group that does great work supporting a broad range of folks who write

Scheduling Note: The plan is for Cost Curve to be off tomorrow, back Monday. If any IRA prices leak, though, I’ll be back at it. I was kind of bummed

This has not been a great week for explanatory takes on the Inflation Reduction Act “negotiation” process. I did some whining yesterday about Reuters’ micron-deep assessment of the situation, and

So there won’t be news this week on the government’s opening offer** around price controls for the first 10 medicines selected under the Inflation Reduction Act. Companies will get the

Gird your loins, everyone.  We’re about to have the most intense 10 days in DrugPricingLand in quite some time. We’re due to have the first oral arguments over a core

The idea that hospitals are marking up prices on medicines -- not by a little, but by a whole lot -- is not a new one. PhRMA has been waving

Tyson Foods has 140,000 employees, which is a huge number of people in most contexts, but not that big a number, if we’re being honest, in the context of U.S.

I’m usually loathe to link to articles that are behind particularly high paywalls, but I’m going to make an exception. If you subscribe to BioCentury, check out this piece on